Icon
+91 94997 68112
Login Register

Emend - (EQ 150, 115 mg BASE/VIAL; Powder, Intravenous)

Fosaprepitant dimeglumine Merck
EQ 150, 115 mg BASE/VIAL; Powder, Intravenous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
More Than 5
More Than 5
Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of high or moderate emetogenic cancer.
Yes
****** *** ******(*****) **** *** ***** ** **** **** ** **** ******* *******- *** *, ****; *******- *** **, **** *** **** ************ *********. **** ***** ***** *** ****** ** ** ****** ****, ***** **** * ****** ** ****** ** ***** ******* **** ****** '*** ** *****. **** ***** ******** ****** ***** ****** ***** *, ****. **** ***** *********** **** ** *********. ******* **** * **** ****** ****** ******, *** **** ***** **** ** **** ****** '*** *** *** ************ *********.
Emend Patent 1 Patent 2
****** **** ** ** (****** *****) *******
****** (*****) **** ** ** (****** *****) *******
********* **** **** ** ** (****** *****) *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** *, **** **** ** ** ******** ******** ** *** **, ****
****** (*****) *** \ ** *** *, **** **** ** ** ******** ************ ******** ** *** **, ****
********* **** ** \ ** *** **, **** **** ** ** ******** ***** **** ****
  1. ***** **, **** : ****** *** ******(*****) ******** ***** ***** *** **** ** **** ******* *******- *** *, ****; *******- *** **, ****.
  2. *** **, **** : ***** ***** * **** ******* ****** ** ******** ***** ** **.
  3. *** *, **** : ***** ***** * **** ******* ****** ** ******** ***** ** **.
  4. *** **, **** : ********** ********* **** ****** ** ****** ******* (*** **, ****)
  5. *** **, **** : ********** ********* **** ****** ** ****** ******* (*** **, ****)
  6. *** **, **** : ***** ***** * **** ******* ********* **** ** ****** ******* (***** *, ****)
  7. *** **, **** : ***** ***** **** ****** '*** ** ***** *** ********* ** ****** *** ******
  8. *** **, **** : ***** ***** **** ****** '*** ** ***** *** ********* ** ********* ****
  9. *** **, **** : ***** ***** * **** ******* ****** ** ****** ******* (***** *, ****)
  10. *** **, **** : ***** ***** **** ****** '*** ** ***** *** ********* ** ******
  11. *** **, **** : ***** ***** * **** ******* *** **** ** *** **** ***** **** ** **** ****** '***.
  12. *** **, **** : ***** ***** **** ****** '*** ** ***** *** ********* ** *** ****
  13. *** *, **** : **** ******** *** ** ****** ** *** ******'* ****** **** * ** **** ** "**" ** ****'* ************* *********** *** *********, **. *** ** ****/****

Emend - (125MG)

Fosaprepitant dimeglumine None
125MG
Less Than $1000 mn
None None
None None
None None
EMEND ® is a substance P/neurokinin 1 (NK1) receptor antagonist. EMEND for oral suspension is indicated • in combination with other antiemetic agents, in patients 6 months of age and older for prevention of: o acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)
Yes
Emend Patent 1 Patent 2
*** *********
************** *********** ** * ********** ******** ********** *********** **** ** * ********** ******** **********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.